लोड हो रहा है...
抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的研究进展
Lung cancer has the highest incidence rate and mortality in China, even in the world, and non-small cell lung cancer (NSCLC) accounts for about 85%. The growth and metastasis of tumor depend on the generation of blood vessels, and anti-angiogenic therapy is playing an increasingly important role, ho...
में बचाया:
| में प्रकाशित: | Zhongguo Fei Ai Za Zhi |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
中国肺癌杂志编辑部
2021
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8143969/ https://ncbi.nlm.nih.gov/pubmed/33819970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.05 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|